Functional Modulation of Crohn's Disease Myofibroblasts by Anti-Tumor Necrosis Factor Antibodies

Gastroenterology

Volumn 133, Issue 1, 2007, Pages 137-149

  Di Sabatino, Antonio ^a   Pender, Sylvia L F ^b   Jackson, Claire L ^b   Prothero, Joanna D ^b   Gordon, John N ^b   Picariello, Lucia ^d   Rovedatti, Laura ^a   Docena, Guillermo ^a   Monteleone, Giovanni ^e   Rampton, David S ^a   Tonelli, Francesco ^d   Corazza, Gino R ^c   MacDonald, Thomas T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADALIMUMAB; CASPASE 3; COLLAGEN; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; LIPOCORTIN 5; MACROPHAGE ELASTASE; NEUTRALIZING ANTIBODY; P55 TUMOR NECROSIS FACTOR RECEPTOR HUMAN IGG FUSION PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1 NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; ASSAY; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENZYME ACTIVATION; ENZYME SYNTHESIS; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MYOFIBROBLAST; PRIORITY JOURNAL; STAINING; WESTERN BLOTTING;

EID: 34447093806     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.04.069     Document Type: Article

References (61)

1. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J., and Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
2. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., and van Deventer S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
3. Geboes K., Rutgeerts P., Opdenakker G., Olson A., Patel K., Wagner C.L., and Marano C.W. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 21 (2005) 1741-1754
4. van Deventer S.J.H. Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 121 (2001) 1242-1246
5. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S., Kikuchi Y., Otsuka J., Okamura S., Fujita S., and Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128 (2005) 376-392
6. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., and Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
7. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., van Montfrans C., Hommes D.W., Peppelenbosch M.P., and van Deventer S.J. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
8. Di Sabatino A., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L., Cifone M.G., and Corazza G.R. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase-dependent pathway in Crohn's disease. Gut 53 (2004) 70-77
9. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., and West A.B. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 277 (1999) C183-C201
10. Baugh M.D., Perry M.J., Hollander A.P., Davies D.R., Cross S.S., Lobo A.J., Taylor C.J., and Evans G.S. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117 (1999) 814-822
11. Pender S.L., and MacDonald T.T. Matrix metalloproteinases and the gut-new roles for old enzymes. Curr Opin Pharmacol 4 (2004) 546-550
12. Nagase H., and Woessner J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
13. Davies D.E., Wicks J., Powell R.M., Puddicombe S.M., and Holgate S.T. Airway remodeling in asthma: new insights. Allergy Clin Immunol 111 (2003) 215-225
14. Vandooren B., Kruithof E., Yu D.T., Rihl M., Gu J., De Rycke L., Van Den Bosch F., Veys E.M., De Keyser F., and Baeten D. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50 (2004) 2942-2953
15. von Lampe B., Barthel B., Coupland S.E., Riecken E.O., and Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47 (2000) 63-73
16. Louis E., Ribbens C., Godon A., Franchimont D., De Groote D., Hardy N., Boniver J., Belaiche J., and Malaise M. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 120 (2000) 241-246
17. Saarialho-Kere U.K., Vaalamo M., Puolakkainen P., Airola K., Parks W.C., and Karjalainen-Lindsberg M.L. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 148 (1996) 519-526
18. Vaalamo M., Karjalainen-Lindsberg M.L., Puolakkainen P., Kere J., and Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 152 (1998) 1005-1014
19. Kirkegaard T., Hansen A., Bruun E., and Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 53 (2004) 701-709
20. Heuschkel R.B., MacDonald T.T., Monteleone G., Bajaj-Elliott M., Smith J.A., and Pender S.L. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47 (2000) 57-62
21. Pender S.L., Fell J.M., Chamow S.M., Ashkenazi A., and MacDonald T.T. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 160 (1998) 4098-4103
22. Leeb S.N., Vogl D., Falk W., Scholmerich J., Rogler G., and Gelbmann C.M. Regulation of migration of human colonic myofibroblasts. Growth Factors 20 (2002) 81-91
23. Leeb S.N., Vogl D., Gunckel M., Kiessling S., Falk W., Goke M., Scholmerich J., Gelbmann C.M., and Rogler G. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 125 (2003) 1341-1354
24. Beil W.J., Weller P.F., Peppercorn M.A., Galli S.J., and Dvorak A.M. Ultrastructural immunogold localization of subcellular sites of TNF-alpha in colonic Crohn's disease. J Leukoc Biol 58 (1995) 284-298
25. Best W.R., Becktel J.M., Singleton J.W., and Kern Jr. F. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
26. Mahida Y.R., Galvin A.M., Gray T., Makh S., McAlindon M.E., Sewell H.F., and Podolsky D.K. Migration of human intestinal lamina propria lymphocytes, macrophages and eosinophils following the loss of surface epithelial cells. Clin Exp Immunol 109 (1997) 377-386
27. Pender S.L., Tickle S.P., Docherty A.J., Howie D., Wathen N.C., and MacDonald T.T. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 158 (1997) 1582-1590
28. Rodriguez L.G., Wu X., and Guan J.L. Wound-healing assay. Methods Mol Biol 294 (2005) 23-29
29. Feinberg M.W., Jain M.K., Werner F., Sibinga N.E., Wiesel P., Wang H., Topper J.N., Perrella M.A., and Lee M.E. Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem 275 (2000) 25766-25773
30. McKaig B.C., McWilliams D., Watson S.A., and Mahida Y.R. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162 (2003) 1355-1360
31. Papadakis K.A., and Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51 (2000) 289-298
32. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L., Leber T.M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Well G., Wood M., and Woolley K. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370 (1994) 555-557
33. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., and Colombel J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
34. Toh M.L., Marotte H., Blond J.L., Jhumka U., Eljaafari A., Mougin B., and Miossec P. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis Rheum 54 (2006) 2109-2118
35. Tanaka T., Yoshimi M., Maeyama T., Hagimoto N., Kuwano K., and Hara N. Resistance to Fas-mediated apoptosis in human lung fibroblast. Eur Respir J 20 (2002) 359-368
36. Jelaska A., and Korn J.H. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43 (2000) 2230-2239
37. Chodon T., Sugihara T., Igawa H.H., Funayama E., and Furukawa H. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol 157 (2000) 1661-1669
38. Stasi R., and Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 116 (2002) 334-337
39. Papadaki H.A., Kritikos H.D., Valatas V., Boumpas D.T., and Eliopoulos G.D. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100 (2002) 474-482
40. Daum S., Bauer U., Foss H.D., Schuppan D., Stein H., Riecken E.O., and Ullrich R. Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 44 (1999) 17-25
41. Ciccocioppo R., Di Sabatino A., Bauer M., Della Riccia D.N., Bizzini F., Biagi F., Cifone M.G., Corazza G.R., and Schuppan D. Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 85 (2005) 397-407
42. Salmela M.T., Pender S.L., Reunala T., MacDonald T., and Saarialho-Kere U. Parallel expression of macrophage metalloelastase (MMP-12) in duodenal and skin lesions of patients with dermatitis herpetiformis. Gut 48 (2001) 496-502
43. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
44. Yao P.M., Maitre B., Delacourt C., Buhler J.M., Harf A., and Lafuma C. Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1beta and TNF-alpha. Am J Physiol 273 (1997) L866-L874
45. Sandborn W.J. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 5 (2005) 10-18
46. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., Tremaine W.J., Johnson T., Diehl N.N., and Zinsmeister A.R. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
47. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11 (2001) 372-377
48. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
49. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., and Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168 (2002) 5342-5351
50. Waetzig G.H., Rosenstiel P., Nikolaus S., Seegert D., and Schreiber S. Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. Gastroenterology 125 (2003) 633-634
51. Rosenstiel P., Agnholt J., Kelsen J., Medici V., Waetzig G.H., Seegert D., and Schreiber S. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease. Gut 54 (2005) 314-315
52. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., and Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
53. Schlaepfer D.D., Hauck C.R., and Sieg D.J. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71 (1999) 435-478
54. Suganuma H., Sato A., Tamura R., and Chida K. Enhanced migration of fibroblasts derived from lungs with fibrotic lesions. Thorax 50 (1995) 984-989
55. Pontz B.F., Albini A., Mensing H., Cantz M., and Muller P. Pattern of collagen synthesis and chemotactic response of fibroblasts derived from mucopolysaccharidosis patients. Exp Cell Res 155 (1984) 457-466
56. Graham M.F. Pathogenesis of intestinal strictures in Crohn's disease-an update. Inflamm Bowel Dis 1 (1995) 220-227
57. Bell S.J., and Kamm M.A. Review article: the clinical role of anti-TNFα antibody treatment in Crohn's disease. Aliment Pharmacol Ther 14 (2000) 501-504
58. Di Sabatino A., Ciccocioppo R., Benazzato L., Sturniolo G.C., and Corazza G.R. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther 19 (2004) 1019-1024
59. Gao Q., Hogezand R.A., Lamers C.B., and Verspaget H.W. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Aliment Pharmacol Ther 20 (2004) 585-592
60. Sorrentino D., Terrosu G., Avellini C., Beltrami C.A., Bresadola V., and Toso F. Prevention of postoperative recurrence of Crohn's disease by infliximab. Eur J Gastroenterol Hepatol 18 (2006) 457-459
61. Lichtenstein G.R., Olson A., Bao W., Travers S., and Diamond R.H. Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn's disease patients. Am J Gastroenterol 97 (2002) S254-S255